Reverse Screening Approach to Identify Potential Anti-cancer Targets of Dipyridamole

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2017 Jan 13

PMID 28077994

Citations 8

Authors

Shu-Min Ge

Dong-Ling Zhan

Shu-Hua Zhang

Li-Qiang Song

Wei-Wei Han

Affiliations

Soon will be listed here.

Abstract

Dipyridamole (DIP) inhibits thrombus formation when given chronically, and causes vasodilation over a short time. To date, DIP can increase the anticancer drugs (5-fluorouracil, methotrexate, piperidine, vincristine) concentration in cancer cells and hence enhance the efficacy of treatment cancer. The inhibition of DIP may result in increased 5-fluorouracil efficacy and diminish the drug side effects. But the actual molecular targets remain unknown. In this study, reverse protein-ligands docking, and quantum mechanics were used to search for the potential molecular targets of DIP. The quantum mechanics calculation was performed by using Gaussian 03 program package. Reverse pharmacophore mapping was used to search for potential molecular target candidates for a given small molecule. The docking study was used for exploring the potential anti-cancer targets of dipyridamole. The two predicted binders with the statistically significant prediction are dihydropyrimidine dehydrogenase (DPD) (PDB Id: 1GTE) and human spindle checkpoint kinase Bub1 (PDB Id: 3E7E). Structure analysis suggests that electrostatic interaction and hydrogen bonding play an important role in their binding process. The strong functional linkage of DIP and 5FU supports our prediction. In conclusion, these results generate a tractable set of anticancer proteins. The exploration of polypharmacology will provide us new opportunities in treating systematic diseases, such as the cancers. The results would generate a tractable set of anticancer target proteins for future experimental validations.

Citing Articles

Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner.

Huang S, Zhang N, Xu C, Huang W, Li D, Li J Cell Oncol (Dordr). 2023; 46(4):953-967.

PMID: 36939950 DOI: 10.1007/s13402-023-00789-7.

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.

Keller M, Rohlf K, Glotzbach A, Leonhardt G, Luke S, Derksen K J Exp Clin Cancer Res. 2023; 42(1):25.

PMID: 36670508 PMC: 9854078. DOI: 10.1186/s13046-022-02578-w.

Drug Therapeutic-Use Class Prediction and Repurposing Using Graph Convolutional Networks.

Chipofya M, Tayara H, Chong K Pharmaceutics. 2021; 13(11).

PMID: 34834320 PMC: 8622176. DOI: 10.3390/pharmaceutics13111906.

Dipyridamole induces the phosphorylation of CREB to promote cancer cell proliferation.

Abdelghany L, El-Mahdy N, Kawabata T, Goto S, Li T Oncol Lett. 2021; 21(4):251.

PMID: 33664815 PMC: 7882894. DOI: 10.3892/ol.2021.12512.

Computational approaches: discovery of GTPase HRas as prospective drug target for 1,3-diazine scaffolds.

Kumar S, Sharma D, Narasimhan B, Ramasamy K, Shah S, Lim S BMC Chem. 2019; 13(1):96.

PMID: 31355369 PMC: 6659553. DOI: 10.1186/s13065-019-0613-8.

References

Wang C, Schwab L, Fan M, Seagroves T, Buolamwini J . Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer. Cancer Prev Res (Phila). 2013; 6(5):437-47. PMC: 3829204. DOI: 10.1158/1940-6207.CAPR-12-0345. View

Yuan B, Xu Y, Woo J, Wang Y, Bae Y, Yoon D . Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 2006; 12(2):405-10. DOI: 10.1158/1078-0432.CCR-05-0903. View

Vasu S, Bandettini W, Hsu L, Kellman P, Leung S, Mancini C . Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013; 15:85. PMC: 3851492. DOI: 10.1186/1532-429X-15-85. View

Buhrman G, de Serrano V, Mattos C . Organic solvents order the dynamic switch II in Ras crystals. Structure. 2003; 11(7):747-51. DOI: 10.1016/s0969-2126(03)00128-x. View

Gomez G, Nardone V, Lotfi-Emran S, Zhao W, Schwartz L . Intracellular adenosine inhibits IgE-dependent degranulation of human skin mast cells. J Clin Immunol. 2013; 33(8):1349-59. PMC: 4429864. DOI: 10.1007/s10875-013-9950-x. View

Liu X, Ouyang S, Yu B, Liu Y, Huang K, Gong J . PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res. 2010; 38(Web Server issue):W609-14. PMC: 2896160. DOI: 10.1093/nar/gkq300. View

Kang J, Yang M, Li B, Qi W, Zhang C, Shokat K . Structure and substrate recruitment of the human spindle checkpoint kinase Bub1. Mol Cell. 2008; 32(3):394-405. PMC: 2644263. DOI: 10.1016/j.molcel.2008.09.017. View

Del Ry S, Morales M, Scali M, Tafi A, Giustarini C, Posteraro F . Effect of concomitant oral chronic dipyridamole therapy on inflammatory cytokines in heart failure patients. Clin Lab. 2013; 59(7-8):843-9. DOI: 10.7754/clin.lab.2012.120816. View

Rodrigues M, Barbosa Jr F, Perussi J . Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells in vitro. Braz J Med Biol Res. 2004; 37(4):591-9. DOI: 10.1590/s0100-879x2004000400017. View

10.

Dobritzsch D, Ricagno S, Schneider G, Schnackerz K, Lindqvist Y . Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer. J Biol Chem. 2002; 277(15):13155-66. DOI: 10.1074/jbc.M111877200. View

11.

Wan H, Xu Y, Zhou G . Dual conductance, negative differential resistance, and rectifying behavior in a molecular device modulated by side groups. J Chem Phys. 2012; 136(18):184704. DOI: 10.1063/1.4712615. View

12.

Mysinger M, Carchia M, Irwin J, Shoichet B . Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem. 2012; 55(14):6582-94. PMC: 3405771. DOI: 10.1021/jm300687e. View

13.

Zhou R, Moench P, Heran C, Lu X, Mathias N, Faria T . pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharm Res. 2005; 22(2):188-92. DOI: 10.1007/s11095-004-1185-3. View

14.

Tsavaris N, Kosmas C, Polyzos A, Genatas K, Vadiaka M, Paliaros P . Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens. Tumori. 2002; 87(5):303-7. DOI: 10.1177/030089160108700505. View

15.

Velichkova P, Himo F . Methyl transfer in glycine N-methyltransferase. A theoretical study. J Phys Chem B. 2006; 109(16):8216-9. DOI: 10.1021/jp0443254. View

16.

Kasprzak J, Wejner-Mik P, Nouri A, Szymczyk E, Krzeminska-Pakula M, Lipiec P . Transthoracic measurement of left coronary artery flow reserve improves the diagnostic value of routine dipyridamole-atropine stress echocardiogram. Arch Med Sci. 2013; 9(5):802-7. PMC: 3832825. DOI: 10.5114/aoms.2013.38673. View

17.

Wang J, Chu P, Chen C, Lin J . idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach. Nucleic Acids Res. 2012; 40(Web Server issue):W393-9. PMC: 3394295. DOI: 10.1093/nar/gks496. View

18.

Liao R, Yu J, Himo F . Reaction mechanism of the trinuclear zinc enzyme phospholipase C: a density functional theory study. J Phys Chem B. 2010; 114(7):2533-40. DOI: 10.1021/jp910992f. View

19.

Burch P, Ghosh C, Schroeder G, Allmer C, Woodhouse C, Goldberg R . Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol. 2000; 23(5):534-7. DOI: 10.1097/00000421-200010000-00021. View

20.

Mahony C, Wolfram K, Cocchetto D, Bjornsson T . Dipyridamol kinetics. Clin Pharmacol Ther. 1982; 31(3):330-8. DOI: 10.1038/clpt.1982.42. View